Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Zappulo

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Medical Hypotheses|April 30, 2013
Etiopathogenesis of autism spectrum disorders: fitting the pieces of the puzzle togetherIvan Gentile, Emanuela Zappulo, Roberto Militerni, et al.
Expert Opinion on Investigational Drugs|July 10, 2015
Beclabuvir for the treatment of hepatitis CIvan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, et al.
Expert Opinion on Drug Discovery|November 14, 2015
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis CIvan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, et al.
Expert Opinion on Drug Safety|June 1, 2018
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosisAntonio Riccardo Buonomo, Emanuela Zappulo, Giulio Viceconte, et al.
Current Medicinal Chemistry|July 10, 2014
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infectionIvan Gentile, Federico Borgia, Antonio Riccardo Buonomo, et al.
Expert Opinion on Investigational Drugs|March 27, 2014
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Federico Borgia, et al.
Expert Opinion on Investigational Drugs|March 3, 2016
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical developmentIvan Gentile, Riccardo Scotto, Emanuela Zappulo, et al.
Reviews on Recent Clinical Trials|December 6, 2018
Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of FungiAlberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Opinion on Pharmacotherapy|January 9, 2020
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis CEmanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, et al.
Reviews on Recent Clinical Trials|May 13, 2022
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experienceAntonio Riccardo Buonomo, Giulio Viceconte, Biagio Pinchera, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Medical Hypotheses|April 30, 2013
Etiopathogenesis of autism spectrum disorders: fitting the pieces of the puzzle togetherIvan Gentile, Emanuela Zappulo, Roberto Militerni, et al.
Expert Opinion on Investigational Drugs|July 10, 2015
Beclabuvir for the treatment of hepatitis CIvan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, et al.
Expert Opinion on Drug Discovery|November 14, 2015
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis CIvan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, et al.
Expert Opinion on Drug Safety|June 1, 2018
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosisAntonio Riccardo Buonomo, Emanuela Zappulo, Giulio Viceconte, et al.
Current Medicinal Chemistry|July 10, 2014
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infectionIvan Gentile, Federico Borgia, Antonio Riccardo Buonomo, et al.
Expert Opinion on Investigational Drugs|March 27, 2014
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Federico Borgia, et al.
Expert Opinion on Investigational Drugs|March 3, 2016
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical developmentIvan Gentile, Riccardo Scotto, Emanuela Zappulo, et al.
Reviews on Recent Clinical Trials|December 6, 2018
Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of FungiAlberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Opinion on Pharmacotherapy|January 9, 2020
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis CEmanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, et al.
Reviews on Recent Clinical Trials|May 13, 2022
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experienceAntonio Riccardo Buonomo, Giulio Viceconte, Biagio Pinchera, et al.
Pageof 8